· Published by Health Canada · Official notice
Health Canada is working with Market Authorization Holders to update the safety labelling for these drugs to provide patients and healthcare professionals with prominent and consistent messaging about the severe and potentially life-threatening risks associated with these drugs.
Benzodiazepines and benzodiazepine-like prescription drugs used to treat sleep and anxiety disorders, certain seizure disorders, and to help relax muscles or relieve muscle spasms.
Patients should discuss any questions or concerns about this safety information with their healthcare professional.
OTTAWA – Benzodiazepines and benzodiazepine-like prescription drugs (commonly referred to as “Z-drugs)—commonly used to treat sleep and anxiety disorders, certain seizure disorders, and to help relax muscles or relieve muscle pain—can lead to problematic use and substance use disorder. To help mitigate these risks, Health Canada is asking manufacturers to update their safety warnings to include more prominent and consistent messaging for patients and healthcare professionals.
The update requested by Health Canada includes language around the risks of:
The update includes labelling to reflect that problematic use of these medications can result in overdose or death, especially when combined with other medicines.
The update also contains information to address the risk of severe and life-threatening withdrawal symptoms that can result from abrupt discontinuation or rapid dose reduction.
The Government of Canada is committed to a broad range of activities to help address Canada’s opioid crisis in the areas of prevention, treatment, harm reduction, and enforcement. As part of this commitment, Health Canada is working to strengthen the labelling of benzodiazepines and benzodiazepine-like drugs to better reflect the serious risks when used with opioid drugs.
| Product Name | Active Ingredient(s) | Formulation | DIN | Company |
|---|---|---|---|---|
|
RIVOTRIL 0.5 TAB RIVOTRIL 2.0 TAB |
Clonazepam | Tablet |
|
Hoffman-La Roche Limited |
| DIASTAT | Diazepam | Gel |
|
Valeant Pharmaceuticals North America Llc. |
| DIAZEPAM 2MG TABLETS, DIAZEPAM 5MG TABLETS, DIAZEPAM 10MG TABLETS | Diazepam | Tablet |
|
Laboratoires Confab Inc. |
| DIAZEPAM INJECTION USP | Diazepam | Solution |
|
Sandoz Canada Inc. |
| VALIUM 5.0 TAB | Diazepam | Tablet |
|
Hoffman-La Roche Limited |
| BIO-DIAZEPAM | Diazepam | Tablet |
|
Biomed Pharma |
| ATIVAN | Lorazepam | Tablet |
|
Pfizer Canada Ulc. |
| LORAZEPAM INJECTION USP | Lorazepam | Solution |
|
Sandoz Canada Inc. |
| XANAX, XANAX TAB 0.5MG, XANAX TAB 1MG, XANAX TS | Alprazoalm | Tablet |
|
Upjohn Canada Ulc. |
| CHLORDIAZEPOXIDE | Chlordiazepoxide hydrochloride | Capsule |
|
AA Pharma Inc. |
| CHLORAX | Chlordiazepoxide hydrochloride - clinidium bromide | Capsule |
|
AA Pharma Inc. |
| LIBRAX | Chlordiazepoxide hydrochloride - clinidium bromide | Capsule |
|
Bausch Health Canada Inc. |
| APO-CLOBAZAM | Clobazam | Tablet |
|
Apotex Inc. |
| FLURAZEPAM | Flurazepam HCl | Capsule |
|
AA Pharma Inc. |
| FLURAZEPAM 15MG CAP, FLURAZEPAM 30MG CAP | Flurazepam HCl | Capsule |
|
Laboratoires Confab Inc. |
| SOM-PAM | Flurazepam HCl | Capsule |
|
Biomed Pharma |
| OXAZEPAM 10MG TAB, OXAZEPAM 15 MG TAB, OXAZEPAM 30MG TAB | Oxazepam | Tablet |
|
Laboratoires Confab Inc. |
| OXPAM | Oxazepam | Tablet |
|
Biomed Pharma |
| MOGADON | Nitrazepam | Tablet |
|
AA Pharma Inc. |
| TRIAZOLAM | Triazolam | Tablet |
|
AA Pharma Inc. |
| RESTORIL | Temazepam | Capsule |
|
AA Pharma Inc. |
| IMOVANE | Zopiclone | Tablet |
|
Sanofi-Aventis Canada Inc. |
| SUBLINOX | Zolpidem Tartrate | Tablet |
|
Bausch Health Canada Inc. |
| ZOLPIDEM TARTRATE ODT | Zolpidem Tartrate | Tablet |
|
Valeant Canada LP/Valeant Canada S.E.C. |
| STARNOC | Zaleplon | Capsule |
|
Pfizer Canada Ulc. |
| LUNESTA | Eszopiclone | Tablet |
|
Sunovion Pharmaceuticals Canada Inc. |
| TEVA-BROMAZEPAM | Bromazepam | Tablet |
|
Teva Canada Limited |
| CLORAZEPATE | Clorazepate dipotassium | Capsule |
|
AA Pharma Inc. |
| PMS-FLURAZEPAM CAP 15MG | Flurazepam HCl | Capsule |
|
Pharmascience Inc |
| MIDAZOLAM INJECTION | Midazolam | Solution |
|
Sandoz Canada Incorporated |
| MIDAZOLAM INJECTION SDZ | Midazolam | Solution |
|
Sandoz Canada Incorporated |
Health Canada is issuing specific instructions to all Market Authorization Holders (MAH) of the impacted products to request these updates.
Health Canada
(613) 957-2983
hc.media.sc@canada.ca
(613) 957-2991
1-866 225-0709